Skip to main content

Advertisement

Table 3 Logistic regression analyses of risk factors for one-year radiographic progression

From: Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study

  OR 95% CI p value*
Univariate analyses
 Female 0.845 (0.373–1.915) 0.687
 Age 0.993 (0.969–1.018) 0.598
 Disease duration 1.004 (1.000–1.008) 0.076
 CHB status 3.129 (1.661–5.895) <0.001
 TJC28 0.996 (0.934–1.063) 0.914
 SJC28 0.982 (0.908–1.062) 0.651
 Pain VAS 1.056 (0.905–1.232) 0.491
 PtGA 1.094 (0.939–1.274) 0.248
 PrGA 1.086 (0.921–1.281) 0.326
 HAQ 1.346 (0.990–1.830) 0.058
 CRP 1.001 (0.998–1.014) 0.876
 ESR 0.999 (0.989–1.008) 0.786
 RF positivity 2.355 (0.921–6.023) 0.074
 ACPA positivity 1.983 (0.775–5.070) 0.153
 DAS28-CRP 1.011 (0.742–1.378) 0.944
 MMP-3 1.001 (0.999–1.002) 0.292
 mTSS 1.016 (1.006–1.026) 0.001
 Treatment-naïveb 0.710 (0.365–1.381) 0.313
 GCs 2.300 (0.964–5.489) 0.061
 MTX 1.369 (0.330–5.678) 0.666
 LEF 0.684 (0.359–1.304) 0.248
 SSZ 1.984 (0.876–4.495) 0.101
 HCQ 1.611 (0.828–3.135) 0.160
 CysA 1.591 (0.490–5.167) 0.440
 Iguratimod 1.130 (0.348–3.670) 0.839
 Biologic agents 0.477 (0.200–1.139) 0.095
 MTX combined with SSZ and HCQ 2.265 (0.949–5.406) 0.066
 MTX combined with LEF 0.719 (0.384–1.346) 0.302
 One-year cumulative dose of GCsc 1.000 (1.000–1.000) 0.010
 One-year cumulative dose of MTX 0.999 (0.998–1.000) 0.224
 One-year cumulative dose of LEFd 1.000 (1.000–1.000) 0.074
 One-year cumulative dose of SSZ 1.001 (1.000–1.003) 0.133
 One-year cumulative dose of HCQ 1.004 (0.998–1.009) 0.160
 One-year cumulative dose of CysAe 1.000 (1.000–1.000) 0.124
 One-year cumulative dose of iguratimodf 1.000 (1.000–1.000) 0.761
 One-year cumulative dose of tocilizumabg 1.000 (0.999–1.000) 0.232
 One-year cumulative dose of Yi Sai Pu 1.000 (0.998–1.003) 0.817
 One-year cumulative dose of infliximab 0.997 (0.989–1.006) 0.564
Bivariate models
 CHB status adjusted for baseline mTSS 2.610 (1.338–5.092) 0.005
 CHB status adjusted for one-year cumulative dose of GCs 2.881 (1.511–5.493) 0.001
Multivariate model
 CHB status adjusted for baseline mTSS and one-year cumulative dose of GCs 2.403 (1.218–4.743) 0.011
  1. ACPA anti-cyclic citrullinated peptide antibody, CHB chronic hepatitis B virus (HBV) infection, CI confidence interval, CRP C-reactive protein, CysA cyclosporin A, DAS28 Disease Activity Score 28-joint assessment, ESR erythrocyte sedimentation rate, GC glucocorticosteroid, HAQ Stanford Health Assessment Questionnaire, HCQ hydroxychloroquine, LEF leflunomide, mTSS modified total Sharp score, MTX methotrexate, OR odds ratio, Pain VAS pain visual analog scale, PrGA provider global assessment of disease activity, PtGA patient global assessment of disease activity, RF rheumatoid factor, SJC28 28-joint swollen joint count, SSZ sulfasalazine, TJC28 28-joint tender joint count
  2. aCalculated using conditional logistic regression analysis. Univariate logistic regression analysis was performed on variables, including baseline characteristics, CHB status, and rheumatoid arthritis medications after enrollment (including categories of medications, one-year cumulative doses of medications, and different regimens of combined therapies); bivariate analysis was performed by adjusting for baseline mTSS and one-year cumulative dose of GCs respectively; multivariate logistic regression analysis was performed by adjusting for all significant univariate factors: bold p values are significant
  3. bWithout glucocorticosteroid or DMARD therapy for 6 months before enrollment
  4. cOne-year cumulative dose of GCs: OR 1.000282, 95% CI 1.000067–1.000497; p = 0.010
  5. dOne-year cumulative dose of LEF: OR 0.999888, 95% CI 0.999766–1.000011; p = 0.074
  6. eOne-year cumulative dose of CysA: OR 1.000025, 95% CI 0.999993–1.000057; p = 0.124
  7. fOne-year cumulative dose of iguratimod: OR 1.000013, 95% CI 0.999926–1.000101; p = 0.761
  8. gOne-year cumulative dose of tocilizumab: OR 0.999719, 95% CI 0.999259–1.000180; p = 0.232